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Objectives: For the treatment of septic arthritis in large animals, the local application of antibiotics as
a slow release system may be an appropriate means to reach high local bioactivity and low systemic
side effects and drug residues. In this study, doxycycline microspheres were developed and tested in
vitro for their drug-release properties, suitability for intra-articular application and antimicrobial
activity.
Methods: The development of a slow release system was achieved by microencapsulation of the drug
into poly(lactide-co-glycolide) microspheres by a novel ultrasonic atomization method. Drug elution
was evaluated from microspheres dispersed in elution medium at pre-defined time points by HPLC.
Joint-tissue compatibility was tested on cultured bovine synoviocytes by evaluating the expression of
pro-inflammatory cytokine mRNA and the production of nitric oxide (NO). Finally, the antimicrobial
activity of the released antibiotic was assessed with Gram-negative and Gram-positive bacteria
exposed to release medium sampled at days 1, 7 and 12 after microsphere suspension.
Results: An adequate size of the microspheres, sufficient stabilization of doxycycline in aqueous
environment and drug release (25 mg microspheres in 4 mL medium) above MIC for bacteria usually
isolated in bovine and equine joints were obtained over 15 days. Although the cytokine mRNA
expression reflected the excellent tissue compatibility, the results with NO yielded contradictory
results. Antimicrobial tests of the release medium proved to match perfectly the activity of non-encap-
sulated, free doxycycline as reported in the literature.
Conclusions: The newly developed doxycycline delivery system achieved the target specifications and
is ready for in vivo testing.
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Introduction
Treatment of septic arthritis in large animals is demanding and
prognosis still guarded.1 – 3 Besides surgical interventions, the
immediate onset of antibiotic therapy is mandatory.4 Local
application of antibiotics has the advantage of providing high
drug concentrations at the site of infection while keeping the
systemic concentrations low, which results in less systemic side
effects and lower drug residues in muscular tissues.5,6
Disadvantages of local drug application are the risk of
joint tissue toxicity and superinfections following repeated
arthrocenteses.4,7
Attempts to overcome the problems of repeated local drug
administration have primarily focused on using slow release for-
mulations of antibiotics.8 Two slow release antibiotic products
are commercially available for human treatment in Switzerland.
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The first consists of gentamicin-containing poly(methylmeth-
acrylate) (PMMA) beads (Septopalw-Ketten, Biomet
Orthopaedics, Ried b.Kerzers, Switzerland), which can be
implanted into infected wounds, septic joints and in the vicinity
of fractured bones. After healing or exhaustion of the antibiotic
activity, the beads have to be removed surgically.9 – 11 The
second marketed formulation is a gentamicin-soaked sponge
made from bovine collagen (Garamycinw Schwamm, Essex
Chemie, Luzern, Switzerland). The collagen sponge is biore-
sorbable and does, therefore, not require a second surgical inter-
vention. Furthermore, it diminishes the risk of developing a
resistant flora as described for the PMMA beads.3,12,13
Conversely, the collagen sponge affords shorter periods of drug
release than the PMMA beads14,15 and possesses the risk of pro-
pagating transmissible spongiform encephalitis.
Investigational studies have considered a variety of antibiotics
and slow release formulations, many of which were based on
PMMA or on biodegradable poly(lactide) or poly(lactide-co-
glycolide) (PLGA).16 – 19 The most commonly used antibiotic in
these studies was gentamicin. Gentamicin covers a broad anti-
biotic spectrum including bacterial pathogens often isolated
from equine joints. However, it is also known for its irritating
activity by inducing a mild and transient synovitis7 and its rela-
tive inefficiency against anaerobic bacteria often isolated from
bovine joints.20 – 22 A good alternative to gentamicin for slow
release formulations designed for the treatment of infected joints
is doxycycline hyclate. Introduced into human pharmacotherapy
in 1967,23 it has proven its antibiotic efficacy against most of
the pathogenic bacteria isolated from inflamed joints of horses
and cattle.23 – 25 However, resistance to tetracyclines is a world-
wide problem. It is due to either decreased intracellular anti-
biotic accumulation caused by inhibition of drug import into the
cell or increased antibiotic efflux, or to a mechanism to protect
cellular ribosomes. Generally, there is cross-bacterial resistance
among tetracycline and doxycycline, but there are several excep-
tions described (e.g. Bacteroides fragilis26 and Streptococcus
pneumoniae23). When focusing on bacteria relevant for septic
arthritis, a general overview about the susceptibility of bacterial
isolates from horses in The Netherlands24 reports some resist-
ance of Escherichia coli and Klebsiella spp., but none of the
tested Streptococci and Staphylococci spp. and Actinobacillus
equuli showed MICs above 2 mg/L. All Staphylococcus aureus
isolates from cattle in Brazil were also susceptible to doxycycline,
whereas 7 of 46 strains were resistant to tetracycline.27
Doxycycline has been reported to be chondroprotective both
in vitro28 – 30 and in human clinical studies.31,32 Our own experi-
ments revealed a very good local tissue compatibility of doxycy-
cline in bovine joints.33
Further critical issues relevant for developing and using slow
release antibiotic formulations are the stability of the antibiotic
in the formulation during the entire release period and the ease
of localized administration, e.g. in infected joints of animals.
Readily administrable slow release formulations are, for
example, biodegradable microspheres made of PLGA. PLGA
microspheres can be administered with a conventional syringe
and needle. Several hormone-containing PLGA products are on
the market for human use to systemically treat different forms of
cancer. When considering the stability issue, many antibiotics
will not be useful for slow release as they degrade quickly, i.e.
within a few hours or days. Examples of unstable antibiotics
include erythromycin, penicillins and cephalosporins, which
hydrolyse quickly upon contact with aqueous media.
Tetracyclines, although not susceptible to hydrolysis, readily
undergo oxidation and epimerization. Nevertheless, doxycycline
is one of the most stable tetracycline group members and has, in
our preliminary experiments, promised to be a good candidate
for slow release formulations.34 The feasibility of microencapsu-
lating tetracycline compounds into PLGA has been demonstrated
for minocycline used to treat periodontitis in man.35
In the present study, we developed slow release PLGA micro-
spheres for the delivery of doxycycline as improved treatment of
infected joints of horses and cattle. The formulations were tested
for the duration of doxycycline release, doxycycline stability,
in vitro toxicity and in vitro antimicrobial activity.
Materials and methods
Doxycycline microencapsulation into
PLGA microspheres
Doxycycline hyclate (Ph. Eur.; Spirig, Egerkingen, Switzerland)
was microencapsulated into PLGA 50:50 (PLGA 50:50,
Resomerw 502 H, Boehringer-Ingelheim, Ingelheim, Germany)
at 10% nominal drug loading. During processing and storage, all
materials were protected from light and oxygen. For a 3 g batch,
300 mg doxycycline was dissolved in 3 mL of methanol, and
this solution was added slowly to a solution of 2.7 g of PLGA
dissolved in 27 mL of acetone. The clear and slightly yellowish
doxycycline/PLGA solution was atomized at a rate of 30 mL/h
through an ultrasonic spray-head (US1, Lechler, Metzingen,
Germany) into 500 mL of octamethylcyclotetrasiloxane
(OMCTS; Abil K-4, Goldschmidt, Essen, Germany) under mod-
erate stirring. At the end of atomization, the slurry was exposed
to a slightly reduced pressure (400 mbar) for 3 h to eliminate
further the solvents and harden the microspheres. The micro-
sphere dispersion in OMCTS was filtered through a 0.2 mm
regenerated cellulose filter (Schleicher & Schuell, Dassel,
Germany), washed three times with 20 mL of cyclohexane and
dried overnight at 308C and 20 mbar. For storage, the micro-
spheres were filled into brown glass vials, purged with argon
and kept at 48C in the dark. A portion of the microspheres was
also subjected to g-irradiation (25 kGy, Studer Hard, Da¨niken,
Switzerland) to test potential instability and degradation during
sterilization.
Determination of microsphere size and
doxycycline loading
Particle size was analysed by laser light diffraction (Mastersizer
X, Malvern, UK). The doxycycline content in the microspheres
was determined by dissolving 10 mg of microspheres (accurately
weighed) in 8.0 mL of acetonitrile and completing the solution
with 2.0 mL of water. The filtered solution (0.45 mm cellulose
acetate filter) was analysed by HPLC,36 using an EZCHROM
Elite Hitachi (Hitachi, VWR International, Dietikon,
Switzerland) with a UV-VIS detector L-2420, an autosampler
L-2200 and a pump L-2130. Separation was performed on a
C8-Phenomenex Luna column (5 mm, 250  4.6 mm;
Brechbu¨hler, Schlieren, Switzerland) under isocratic conditions
using as mobile phase a degassed mixture of acetonitrile/water/
perchloric acid (26:74:0.25, by vol.) adjusted to pH 2.5 with
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5 M sodium hydroxide. The flow rate was 1.0 mL/min, and dox-
ycycline was detected at 350 nm.
In vitro doxycycline release testing
Microspheres (20 mg, accurately weighed) were filled in 4.5 mL
amber borosilicate screw-top vials (BGB Analytik, Adliswil,
Switzerland) and dispersed in 4.0 mL of release medium. The
release medium consisted of a 0.1 M citrate buffer of pH 5.0,
supplemented with 0.01% (w/w) sodium azide, 0.01% (w/w)
poloxamer 188 and 0.01% sodium EDTA. The vials were
installed in a drum rotating at 3 rpm and placed at 378C. At
regular time intervals, the entire release medium of four vials
was withdrawn and analysed by HPLC, as described in the pre-
vious section. The remaining polymeric pellets were dried under
vacuum overnight, and the non-released doxycycline extracted
and analysed by HPLC as described in the previous section.
In vitro toxicity testing of doxycycline
and doxycycline-loaded microspheres on
cultured bovine synoviocytes
Establishment of bovine synovial cell cultures. Synovial membranes
of four calves and two cows (aged between 6 months and 4 years),
who were routinely slaughtered in a local abattoir, were harvested
aseptically from fetlock (metacarpo/tarso-phalangeal) joint. A separ-
ate culture was prepared for each animal. After two washes in
saline, the membranes were cut into small pieces of 1 mm2,
placed into the inner part of a two-compartment digestion
chamber,37 pre-treated with 0.2% trypsin at 378C for 30 min and
subsequently digested enzymatically with 0.2% collagenase for 2 h
at 378C under constant movement. The cells were collected from
the outer compartment of the digestion chamber, washed three
times with Dulbecco’s modified Eagle’s medium (DMEM; Gibco,
Invitrogen, Basel, Switzerland) containing 10% fetal bovine serum
and subsequently seeded in six-well plates (Falcon Comanion Plate
6 Wells, Milian, Meyrin, Switzerland) at 100 000 cells per well.
For maintenance, the cells were cultured at 95% humidity, 5%
CO2 and 378C for 7–8 days until confluence, with the medium
being changed every 2–3 days.
Cytotoxicity testing. Preliminary tests were performed to evaluate
the cytotoxicity of bacterial lipopolysaccharide (LPS) using different
concentrations and incubating over different periods of time.
Incubation time and concentrations were chosen to prevent enhanced
cell death. Cell numbers were assessed using a cell viability test
based on cleavage of tetrazolium salt (Cell Proliferation Reagent
WST-1, Roche Diagnostics, Mannheim Germany). b-Actin-
messenger RNA levels proved to correlate significantly (P, 0.001)
with the viability test and were thus chosen for normalization.
For toxicity experiments, the cells were vigorously washed
with phosphate-buffered saline (PBS) containing 0.2 g/L KCl,
1.0 g/L NaHCO3 and 1 g/L glucose monohydrate and treated
with (i) plain DMEM (negative control), (ii) 100 mg/L LPS
(Sigma-Aldrich, Buchs SG, Switzerland) (positive control), (iii)
1 mg/mL doxycycline in solution (Vibravenoesw, Pfizer, Zurich
Switzerland), (iv) 0.2 mg/mL microspheres (low-dose micro-
spheres; 20 mg/mL doxycycline), and (v) 5 mg/mL micro-
spheres (high-dose microspheres; 500 mg/mL doxycycline). For
incubation, all test materials (LPS, doxycycline, and micro-
spheres) were dissolved or suspended in DMEM; incubation
lasted for 4 or 24 h. With the high-dose microspheres, the cells
were completely and firmly covered with the microspheres, which
compromised the further separation and lysis of the cells. Hence,
an insert (Falcon 0.4 mm HD Inserts, Milian) was used for the
high-dose microspheres to allow separation of microspheres and
cells and to facilitate the collection of the cells. The supernatant
of all cell samples was collected and kept at 2808C until further
use. The cells were lysed in TRI Reagentw (Molecular Research
Center, Cincinnati, OH, USA), their RNA extracted following the
manufacturer’s instructions and the extracts kept at 2808C until
further processing. Each test was performed in triplicate.
The differently treated synoviocytes were analysed for the
production of interleukin (IL)-1b, IL-6 and tumour necrosis
factor (TNF)-a mRNA by RT–PCR. b-Actin was used as the
housekeeping gene. The primers and probes (Table 1; all from
Microsynth, Balgach, Switzerland) were designed on the basis
of the GenBank database and with the help of the Primer
Express Oligo Design software version 1.5 (Applied Biosystems,
Foster City, CA, USA). The probes were designed to contain an
exon–exon junction overlapping sequence to exclude the
measuring of genomic DNA and they were labelled with the
reporter molecule 6-carboxyfluorescein (FAM) at the 50 ends
and with the quencher molecule 6-carboxy-N,N,N0,
N0-tetramethylrhodamine (TAMRA) at the 30 ends. As a refer-
ence, cDNA from stimulated bovine macrophages (kindly pro-
vided by Prof. T. Jungi, Institute of Immunology, Vetsuisse
Faculty, University of Berne, Berne, Switzerland) was used for
assessing the efficiency of multiplication and calculating the
mRNA content (eff2x).
Reverse transcription of 1 mg of RNA per cell sample was
performed with TaqMan reverse transcription reagents (Applied
Biosystems) using random hexamer primers. PCR was carried
Table 1. Primers and probes used for real-time RT–PCR of cytokines and the corresponding multiplication efficiency factors
Gene Forward primer Reverse primer Probe Efficiency
IL-1b 50-TTA CTA CAG TGA CGA GAA
TGA GCT GTT
50-GGT CCA GGT GTT GGA TGC
A
50-CTC TTC ATC TGT TTA GGG
TCA TCA GCC TCA A
1.724
IL-6 50-ACT GGC AGA AAA TAA GCT
GAA TCT TC
50-TGA TCA AGC AAA TCG CCT
GAT
50-AAC CCA GAT TGG AAG CAT
CCG TCC TTT
1.788
TNF 50-CCT CTT CTC AAG CCT CAA
GTA ACA A
50-GAG CTG CCC CGG AGA GTT 50-ATG TCG GCT ACA ACG TGG
GCT ACC G
1.84
b-Actin 50-CGG CAC CAG GGC GTA AT 50-TCT CCA TGT CGT CCC AGT
TG
50-AGC AAG AGA GGC ATC CTG
ACC CTC AAG T
1.79
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out in 24 mL reactions with 900 nM of each primer, 250 nM of
labelled probe and Universal PCR master mix (Applied
Biosystems) under standard thermal conditions with an AB 7500
Real Time PCR System (Applied Biosystems).
The nitric oxide (NO) release from the synoviocytes incu-
bated during 24 h with doxycycline solution, doxycycline-loaded
microspheres and control samples was examined using the Total
NO/Nitrite/Nitrate Assay (R&D Systems, Bu¨hlmann
Laboratories, Scho¨nenbuch, Switzerland), which is based on the
Griess reaction. The amounts of NO were normalized to the
amount of b-actin mRNA.
Contents of mRNA and NO were expressed relative to the
amounts of the negative control (DMEM) at 4 h (mRNA) and
24 h (NO). Statistical data analysis was performed using the
Number Cruncher Statistical System (Kaysville, UT, USA).
Groups were compared using one-way analysis of variance
(ANOVA), and the P value was set at 0.05.
In vitro antimicrobial activity testing of doxycycline
released from microspheres
Release test medium from six samples, each of non-irradiated
and g-irradiated doxycycline-loaded microsphere preparations
(see the section on Doxycycline microencapsulation into PLGA
microspheres), was used for the assessment of the antimicrobial
activity of doxycycline released after 1, 7 and 12 days. The day
before the sampling of the release test medium for microbial
testing, the entire release medium was discarded and replaced by
fresh release medium (see the section on In vitro doxycycline
release testing; medium without sodium azide). This procedure
eliminated any doxycycline-degradation products developing in
the release medium over time and considered only the amount
of doxycycline released within 24 h at the above indicated time
points. Samples were stored at 2208C until further use. Before
performing the antibacterial tests, the doxycycline concentration
was assessed for every sample with the HPLC analysis (see the
section on Determination of microsphere size and doxycycline
loading).
The in vitro antibacterial activity of the released doxycycline
against S. aureus ATCC 25923 and E. coli ATCC 25922 was
determined using the microdilution method in cation-adjusted
Mueller–Hinton broth (CAMBH), according to the CLSI guide-
lines.38 Doxycycline hyclate solutions in citrate buffer (concen-
trations from 64 to 0.125 mg/L) served as reference dilutions
and plain elution buffer as negative control. Release test samples
from microspheres were pre-diluted or used undiluted according
to the results from HPLC measurements. Every sample was sub-
jected to serial dilutions in order to evaluate the individual MIC
as calculated from the number of dilution steps. Bacterial cul-
tures were expanded in CAMBH at 378C for 4–6 h. Inocula
were adjusted to 1  106 bacteria/mL nephelometrically, using
standardization curves determined in earlier studies. Microtitre
plates (U-shaped bottom; Greiner, Frickenhausen, Germany)
were loaded with 50 mL of serially diluted release testing
samples and controls. To each well, 50 mL of standard inoculum
was added and incubated for 24 h. The MIC was read as the
lowest concentration without visible growth.
Statistical analysis
The data were statistically analysed by ANOVA and Bonferroni
post hoc test. P values less than 0.05 were considered
significant.
Results
Yield, size and doxycycline content of the microspheres
The product yield was in the range of 70% to 75%, and the
volume weighted particle size range was between 15 and
120 mm with a mean diameter of 35 mm. The doxycycline
content in the non-irradiated and g-irradiated microspheres
amounted to 82 and 77 mg/mg microspheres, respectively, corre-
sponding to an encapsulation efficiency of more than 80%. No
differences were observed in the HPLC chromatograms between
non-irradiated and irradiated samples in terms of additional
peaks, thus excluding potential doxycycline degradation
Figure 1. Doxycycline release profiles from non-irradiated (open circles)
and g-irradiated (25 kGy) (filled circles) PLGA 50:50 microspheres. (a)
Doxycycline release directly measured in the test medium. (b) Doxycycline
release determined as the difference between the primary doxycycline
content of microspheres and the amount of non-released doxycycline that
remained in the polymeric pellet at the indicated time points.
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products. Therefore, in microencapsulated form, doxycycline
appeared to remain stable during g-irradiation.
In vitro release of doxycycline
To assess the stability of doxycycline at 378C over prolonged
periods of time, the amount of released doxycycline was
assessed in two ways: by analysing doxycycline in the release
medium (Figure 1a) and by determining the amount of non-
released doxycycline in the remaining polymeric mass
(Figure 1b). Both analytical methods revealed a triphasic release
profile, lasting 15 days, and no significant differences were
found between non-irradiated and g-irradiated microspheres
(Figure 1).
When doxycycline was analysed in the release medium, the
triphasic release profile consisted of an initial burst amounting
to 30 mg/mg microspheres, a period of very little doxycycline
release that lasted 3 days, and a final phase of almost constant
release of an additional 30 mg/mg microspheres between days
4 and 15 (Figure 1a). After day 15, a slight decrease suggested
some degradation of doxycycline in the release medium, which
was confirmed by the appearance of an additional elution peak
in the HPLC chromatograms (R. Alder and A. Pickl, data not
shown). Thus, 20 mg doxycycline/mg microspheres degraded
in the release medium within 15 days of incubation.
Calculating from the amount of non-released doxycycline in
the remaining polymeric mass, both the burst (58 mg/mg micro-
spheres) and the total amount released (98 mg/mg microspheres)
were higher (Figure 1b), and there was no apparent loss of material
after completion on day 15. The apparently excessive total
amount of doxycycline released (98 mg/mg microspheres versus
82 mg/mg microspheres doxycycline loading) must be ascribed to
small yet cumulative quantities of doxycycline remaining in the
vials (remaining release medium, vial wall, adsorbed on the
surface of polymer pellet) each time the release medium was with-
drawn; these residual amounts of doxycycline in the vial were
added to the amount of non-released doxycycline, as the remain-
ing polymeric material was dissolved in the vial itself.
In vitro toxicity of doxycycline and doxycycline-loaded
microspheres on cultured bovine synoviocytes
The synoviocytes incubated for 4 h with doxycycline or
doxycycline-loaded microspheres expressed similar amounts of
cytokine-specific mRNA to those incubated with plain medium,
but significantly less than the positive control cells stimulated
with LPS (P , 0.01) (Figure 2). When normalizing the mRNA
levels of the treated cells against the negative control cells (incu-
bated with plain medium), the IL-1b-specific mRNA was
increased by factors of 1.2 (plain doxycycline), 1.5 (low-dose
microspheres), 1.8 (high-dose microspheres) and 11.0 (positive
LPS control) (Figure 2a). For the IL-6-specific mRNA
(Figure 2b), the relative changes of expression level over that
observed with the negative control cells were 3.4 with plain
doxycycline, 1.0 with the low-dose microspheres, 0.7 with the
high-dose microspheres and 33.2 with the LPS control. For the
TNF-a-specific mRNA (Figure 2c), the relative changes were
2.0 with the plain doxycycline, 1.8 with the low-dose micro-
spheres, 2.9 with the high-dose microspheres and 39.3 with the
positive control.
After 24 h of incubation, the mRNA expression levels
changed variably depending on the treatment. When compared
with the negative control at 24 h, the IL-1b-specific mRNA (C.
Haerdi-Landerer, data not shown) did not change with plain
doxycycline, but increased by a factor of 29.0 in the positive
control and decreased by factors of 0.7 and 0.1 with the
low-dose and high-dose microspheres, respectively. For the non-
stimulated cells, the increase in IL-1b mRNA expression
between 4 and 24 h was 1.3-fold. The IL-6 mRNA
(C. Haerdi-Landerer, data not shown) increased by factors of
13.1 (plain doxycycline), 239.8 (positive control) and 1.9
(high-dose microspheres), but decreased slightly (by a factor of
0.9) with the low-dose microspheres when compared with the
negative control at 24 h. For the negative control cells, the IL-6
mRNA expression decreased by the factor of 0.34 between 4
and 24 h. Finally, the TNF-a mRNA levels (Figure 3) at 24 h
were increased by factors of 10.4 (positive control), 3.6 (plain
doxycycline), 1.03 (low-dose microspheres), and 7.8 (high-dose
Figure 2. Relative mRNA content of (a) IL-1b, (b) IL-6 and (c) TNF-a
produced by cells stimulated for 4 h with 1 mg/mL plain doxycycline
(DOX), 5 mg/mL microspheres (500 mg/mL doxycycline) (MS high) and
0.2 mg/mL microspheres (20 mg/mL doxycycline) (MS low). The negative
control (NEG) was performed with the plain culture medium and the positive
control (POS) was performed with the medium containing 100 mg/mL
LPS. , outlier.
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microspheres) in comparison with the negative control cells. At
this time point, only the TNF-a mRNA content of the synovio-
cytes incubated with the low-dose microspheres was signifi-
cantly below the value of the positive control cells (P ¼ 0.0023)
(Figure 3). In the negative control cells, the TNF-a mRNA
expression increased by a factor of 3.6 between 4 and 24 h.
NO production by the synoviocytes appeared to be increased
in the positive control and the high-dose microsphere groups
when compared with the negative control and the low-dose
microsphere groups. Nonetheless, the statistical differences were
only weak in the ANOVA (P ¼ 0.048), and no significant differ-
ence was observed between any of the groups when using the
Bonferroni post hoc test (Figure 4). When the amounts of NO
were normalized to the amount of b-actin mRNA isolated from
the cells of the same well, the NO contents were increased, rela-
tive to the negative control cells, by factors of 26.4 for the posi-
tive control, 3.4 for the plain doxycycline, and 10.5 and 119.4
for the low-dose and high-dose microsphere groups,
respectively.
In vitro antimicrobial activity of doxycycline released
from microspheres
HPLC measurements of doxycycline in release media of micro-
spheres revealed mean values of 200.5 + 8.2 mg/L for day 1,
14.1 + 5.2 mg/L for day 7 and 22.4 + 1.1 mg/L for day 12.
Thus, day 1 media were diluted 1:9 before starting serial
dilution. With E. coli ATCC 25922, ranges of MICs for doxy-
cycline in the release medium were 0.6–1.26 mg/L for day 1
samples, 0.41–0.92 mg/L for day 7 samples and 0.66–0.75 mg/L
for day 12 samples. With S. aureus ATCC 25923, the MIC
value ranges were 0.15–0.32 mg/L for day 1, 0.15–0.46 mg/L
for day 7 and 0.16–0.19 mg/L for day 12. Thus, the MIC values
of released doxycycline against both bacterial strains were kept
within the limits in terms of strain-specific CLSI doxycycline
reference MIC values (E. coli: 0.5–2.0 and S. aureus: 0.12–
0.5). No differences were found between the three different time
points or between samples from g-irradiated and non-irradiated
microspheres. Overall, the antimicrobial activity of doxycycline
released from microspheres after 1, 7 and 12 days generally
coincided with the original substance.
Discussion
The aim of this study was to produce doxycycline-containing
microspheres at high yield, with good encapsulation efficiency,
particle sizes above the threshold for uptake by phagocytes, con-
trolled antibiotic release over 14 days, low inflammatory reac-
tion and intact antibiotic activity. Further, the controlled release
and bioactivity of the formulation should remain unaltered upon
sterilization by g-irradiation. These specifications, defined in
view of subsequently using the delivery system for the localized
and prolonged treatment of septic arthritis in large animals, were
all successfully met in this study.
The microencapsulation of antibiotics generally faces some
of the following hurdles: drug degradation, modest encapsulation
efficiency, alteration by sterilization or scaling-up difficulties.
Different methods for microencapsulation of antibiotics have
been described.35,39,40 Spray-drying was excluded, because it is
known to yield, at least with laboratory spray-dryers, small par-
ticles (diameters of 0.1–10 mm) that are highly susceptible to
phagocytosis, especially in inflamed tissue. The solvent extrac-
tion/evaporation methods generally yield modest encapsulation
efficiency with highly water-soluble drugs, besides being diffi-
cult to scale up. Indeed, our own preliminary experiments con-
firmed a very low encapsulation efficiency of doxycycline in
PLGA 50:50 microspheres when using a microextrusion-based
solvent extraction method (S. Fischer and B. Gander, unpub-
lished results). The method developed in this study was tailored
to the particular materials used and the pre-defined aforemen-
tioned specifications. The ultrasonic atomization of the organic
doxycycline–PLGA solution into the non-solvent OMCTS
Figure 3. Relative content of TNF-a mRNA of cells stimulated for 4 h
(empty boxes) and 24 h (grey boxes) with 1 mg/mL plain doxycycline
(DOX), 5 mg/mL microspheres (500 mg/mL doxycycline) (MS high) and
0.2 mg/mL microspheres (20 mg/mL doxycycline) (MS low). The negative
control (NEG) was performed with the plain culture medium and the positive
control (POS) was performed with the medium containing 100 mg/mL
LPS. , outlier.
Figure 4. Relative content of NO in the cell supernatant after 24 h of
stimulation with 1 mg/mL plain doxycycline (DOX), 5 mg/mL microspheres
(500 mg/mL doxycycline) (MS high) and 0.2 mg/mL microspheres (20 mg/mL
doxycycline) (MS low). The negative control (NEG) was performed with plain
culture medium and the positive control (POS) was performed with medium
containing 100 mg/mL LPS. , outlier.
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produced the desired particle size range at a high yield. The
absence of water in the process was most favourable for the high
encapsulation efficiency and preservation of the doxycycline
stability. Furthermore, the method can be readily scaled-up and
transferred to an industrial setting.
Drug stability is definitely the first prerequisite for prolonged
release over the desired time interval of 10–15 days. Many anti-
biotics such as penicillins, cephalosporins and erythromycin are
sensitive to humidity and hydrolyse in the presence of water.
These drugs are obviously unsuitable for prolonged release from
PLGA microspheres, which release entrapped drugs by diffusion
upon hydration of the particles in water and hydrolytic degra-
dation of the polyester. Our own attempts to microencapsulate a
cephalosporin compound into PLGA failed badly, because we
were unable to slow down sufficiently the hydrolysis of the drug
(S. Fischer and B. Gander, unpublished results). For the intended
therapeutic use, a good alternative to cephalosporins are the
tetracyclines. Tetracycline and its analogues do not undergo
hydrolysis, but are susceptible to photolysis, epimerization and
isomerization.34,36 Doxycycline hyclate was selected for our
work, because it is one of the most stable tetracycline analogues
and it is already successfully used in drug delivery systems
(DOXYw, Vivadent Ivoclar, Schaan, Liechtenstein; Atridoxw,
CollaGenex Pharmaceuticals, Newtown, PA, USA) for periodon-
tal application. For developing a suitable in vitro release test
medium for the doxycycline-loaded microspheres, preliminary
stability experiments were conducted in different buffer systems
and by the addition of putative stabilizers. Here, an enhanced
doxycycline stability was noticed in pure water and citrate buffer
of pH 5.0 over PBS of pH 7.4 (20% versus 30% degradation
within 7 days at 378C). A further improvement was achieved by
adding sodium EDTA (0.01%) to the citrate buffer (12% degra-
dation within 7 days at 378C) (A. Pickl and B. Gander, data not
shown).
The in vitro doxycycline release from the PLGA 50:50
microspheres in the optimized medium lasted for 14 days. The
initial burst was expected for the highly water-soluble antibiotic
and should be appropriate to reach an immediate biologically
active antibiotic concentration. The apparent total release was,
however, substantially lower when doxycycline was analysed in
the release medium when estimated from the amount of non-
released drug (Figure 1a versus 1b). This demonstrates good pro-
tection of doxycycline within the PLGA microspheres against
epimerization and oxidation. Furthermore, g-irradiation did not
significantly degrade doxycycline within the microspheres or
alter the in vitro release profile. This negligible effect is
especially important in view of developing a product for
parenteral application; it was, however, surprising because
many, if not most, of the published studies on the g-irradiation
of PLGA-encapsulated drugs reveal significant drug degradation
and accelerated drug release after irradiation of the micro-
spheres.41,42 We may speculate that the absence of water during
microencapsulation yielded a product with very low residual
humidity. Therefore, the amount of H† and OH† radicals formed
during irradiation may have been extremely low, thus limiting
substantially any subsequent radiolysis of drug or polymer.
Importantly, the feasibility of g-irradiation of the doxycycline-
loaded microspheres facilitates greatly the production of con-
trolled release doxycycline for improving the therapy of septic
arthritis in large animals.
As an endeavour to reduce animal tests, cultured synovio-
cytes from several species have been used for tissue compatibil-
ity testing of drugs.43,44 In joint tissues, inflammation and matrix
degradation have been strongly associated with increased levels
of the cytokines IL-1b, IL-6 and TNF-a. Thus, these markers
are often used as parameters for the evaluation of joint irritation
and inflammation.43,45,46 In our study, we noticed significant
differences of cytokine mRNA expression in bovine synovial
cells treated with and without bacterial LPS, which demonstrates
the suitability of this test system for evaluating the in vitro cell
compatibility of the developed delivery system. The minimal
changes of cytokine expression observed with the doxycycline-
loaded microspheres, when compared with the negative control,
suggest a very good tissue compatibility of the microsphere for-
mulation. The apparent impact of the duration of incubation on
the TNF-a expression was surprising. A nearly 4-fold increase
in TNF-a mRNA expression was observed from 4 to 24 h of
incubation in the negative control cells. This must be assigned
to the absence of fetal bovine serum. Furthermore, the starved
cells were less tolerant to the exposure to plain doxycycline or
the high-dose microspheres.
Another marker of tissue irritation and inflammation is NO.
NO production by cultured synoviocytes has been used as a
parameter for tissue irritation in horses,47 humans48 and
rabbits.49 However, regulation of NO synthases differs between
different species and also between different tissues.50,51
Nevertheless, the increased NO content in the supernatant of the
cells stimulated with the doxycycline-containing microspheres
has to be taken into account when interpreting the overall reac-
tion of cultured synoviocytes to the delivery system. NO has
been reported to act as inflammatory mediator, but its action
within the cascade is contradictory, exerting protective as well
as pro-inflammatory and catabolic activities on the cartilaginous
matrix.52,53 Therefore, conclusive answers will only be obtained
through in vivo experiments.
The antimicrobial tests proved the biological activity of the
doxycycline released from both the non-irradiated and
g-irradiated microspheres. The MICs of the doxycycline released
from the microspheres conformed exactly to the values reported
in the literature, i.e. 0.5–2.0 mg/L for E. coli and 0.12–0.5
mg/L for S. aureus.38
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